Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

SALE: 200+ Cancer-related patent PDFs



 Method for early detection of cancer patent thumbnailMethod for early detection of cancer
The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated o-glycans.
Go Therapeutics, Inc.


 A  prognosis of ovarian cancer, patient's stratification patent thumbnailA prognosis of ovarian cancer, patient's stratification
There are no reliable clinical bio-markers of survival prognosis, patient's risk stratification and treatment prediction for epithelial ovarian cancers(eoc). The most common type of the human eoc is a high grade serous eoc.
Agency For Science, Technology And Research


 Pancreatic cancer diagnostic patent thumbnailPancreatic cancer diagnostic
The present disclosure provides methods of using certain biomarker expression profiles in the detection, diagnosis, prognosis, or development of treatment regimens for various cellular hyperproliferative disorders of the pancreas. For example, methods comprise detecting whether the concentration of erbb2, esr1, and tnc in a test biological sample from a subject is elevated as compared to a control..
Fred Hutchinson Cancer Research Center


 Peptides for targeting gastric cancer, and medical use tehreof patent thumbnailPeptides for targeting gastric cancer, and medical use tehreof
Provided is a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide, wherein a functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients.. .
University Of Ulsan Foundation For Industry Cooperation


 Detection of lung neoplasia by amplification of rna sequences patent thumbnailDetection of lung neoplasia by amplification of rna sequences
Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.. .
Exact Sciences Corporation


 Nlrc5 as a biomarker for cancer patients and a target for cancer therapy patent thumbnailNlrc5 as a biomarker for cancer patients and a target for cancer therapy
The invention pertains to biomarkers for identifying a cancer that is likely or not likely to evade the immune system of a subject, thus, is likely or not likely to show better prognosis (prognostic biomarker) and/or better responses to cancer therapies (predictive biomarker). The invention provides a method of identifying a subject as having a cancer that is likely to evade the immune system of the subject based on one or more of the following biomarkers in the cancer cells of the subject: a) reduced amount of nlrc5 mrna or protein; b) reduced activity of nlrc5 protein; c) a mutation that reduces the activity of nlrc5 protein; d) increased methylation of nlrc5 or a portion thereof; and e) reduced copy number of nlrc5.
The Texas A&m University System


 Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment patent thumbnailMethods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment
The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of hgsta1 in a tumor sample obtained from the subject, ii) comparing the expression level determined at step i) with its predetermined reference value and ii) concluding that the subject suffers from a cancer when the expression level of hgsta1 is lower than its predetermined reference value..
Affichem


 Improved treatments of cancer resistant to taxoids patent thumbnailImproved treatments of cancer resistant to taxoids
The present invention relates to improved treatments of cancer resistant to a molecule of the taxoid family. It also relates to methods for selecting a patient affected with a tumor for a treatment with a molecule of the taxoid family in combination with a compound inhibiting the tgf-β signalling pathway or for determining whether a patient affected with a tumor is susceptible to benefit from a treatment with a molecule of the taxoid family in combination with a compound inhibiting the tgf-β signalling pathway as well as methods for screening or identifying a compound suitable for improving the treatment of a cancer with a molecule of the taxoid family or for reducing the resistance development during the treatment.
Institut Gustave Roussy


 Surface modification method patent thumbnailSurface modification method
Provided are methods for surface-modifying a thermoplastic resin which produce surfaces that show not only low adsorption of proteins and cells but also selective adsorption or adhesion of specific cells such as cancer cells, and further have excellent durability. A method for surface-modifying an object made of a thermoplastic resin, the method including: step 1 of forming polymerization initiation points on the surface of the object; and step 2 of radically polymerizing at least a hydrophilic monomer starting from the polymerization initiation points by irradiation with uv light having a wavelength of 300 to 400 nm to form a graft layer having a thickness of 2 to 100 nm on the surface of the object..
Yamagata University


 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof patent thumbnailAnti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.


Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of cancer and angiogenesis related diseases using cyclic peptides.. .
Ruprecht-karls-universitÄt

Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal t cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (myco) bacterially and/or virally infected cells or tumor cells.
Academisch Ziekenhuis Leiden

Immunotherapy against several tumors, such as lung cancer, including nsclc

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer.
Immatics Biotechnologies Gmbh

Maleate salts of (e)-n--4-(dimethylamino)-2-butenamide and crystalline forms thereof

The present invention relates to maleate salt forms of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinollnyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family..
Wyeth Llc

Novel aspirin derivatives and uses thereof

The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer..
North Carolina Agricultural And Technical State University

Medical analysis device and cell analysis method

Provided are a medical analysis device and a cell analysis method which can capture many cancer cells, including cancer cells not expressing epcam. A medical analysis device including a flow channel zone that includes a chamber zone, the inner surface of the flow channel zone being at least partially provided with a layer of a hydrophilic polymer having a thickness of 2 to 200 nm..
Yamagata University

Psma-targeted nir dyes and their uses

The present disclosure relates to prostate specific membrane antigen (psma) targeted compounds conjugated to near-infra red (nir) dyes and methods for their therapeutic and diagnostic use. More specifically, this disclosure provides compounds and methods for diagnosing and treating diseases associated with cells and/or vasculature expressing prostate specific membrane antigen (psma), such as prostate cancer and related diseases.
On Target Laboratories, Llc

Egfr antibody conjugates

A maytansinoid is covalently linked through a non-cleavable linker to an egfr antibody that is a full egfr antagonist, such as cetuximab or panitumumab. The result is an anti-cancer agent having cytotoxicity that is potentiated in cancer cells but not normal cells.
Formation Biologics Inc.

Anti-ar agent and radiation therapy for androgen receptor positive cancer

Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., enzalutamide or anti-androgen antibody), and then treating with radiation therapy.. .
The Cleveland Clinic Foundation

Combination therapy for treating breast cancer

The invention provides compositions and methods for treating breast cancer. Specifically, the invention relates to administering a transforming growth factor beta (tgfβ) antagonist in combination with capecitabine and ixabepilone to treat breast cancer..
Genzyme Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Immunotherapy against several tumors, such as lung cancer, including nsclc

A method of treating a patient who has non-small cell lung carcinoma (nsclc), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has nsclc, lung cancer, gastric cancer, and/or glioblastoma.
Immatics Biotechnologies Gmbh

Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers

The present disclosure relates to methods and pharmaceutical compositions for the treatment of prostate cancers. In particular, the present invention relates to an ox1r agonist for use in the treatment of prostate cancer in a subject in need thereof..
Universite Paris Diderot - Paris 7

Method of treating a bladder cancer using a chimeric egf-targeted bacterial toxin

Provided is a method of treating a bladder cancer in an animal or human comprising: administering to an animal or human patient a therapeutic composition comprising a first fusion protein capable of specifically binding to an epidermal growth factor receptor (egfr) on the surface of a cancer cell and comprising an epidermal growth factor (egf) polypeptide conjugated to a bacterial toxin polypeptide and a second fusion protein comprising an anthrax lethal factor n-terminus (lfn) conjugated to a diptheria toxin a (dta) catalytic domain.. .
Purdue Research Foundation

High activity tumour inhibitor and preparation method and use thereof

Provided in the present invention are a yap protein inhibiting polypeptide and application thereof. In particular, the present invention obtains a key binding site of yap protein and tead, screens a polypeptide with best yap inhibitory activity and modifies the polypeptide, such as adding a disulfide linkage, replacing an amino acid, removing and/or adding (for example, adding a cell-penetrating element), and finally screens and verifies the obtaining of a series of polypeptides with yap protein activity inhibiting effect and good stability.
Bao Kang Biomedical Healthcare Inc

Oncolytic viruses & methods of use thereof

Modified and improved oncolytic viruses (and methods of use thereof) are disclosed. More particularly, modified and oncolytic human herpesviruses (and methods of use thereof) are disclosed, which include a modified amino acid sequence that includes a deletion in a region that represents the amino terminus of glycoprotein k.

Methods of reducing mammographic breast density and/or breast cancer risk

The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain.
Havah Therapeutics Pty Ltd.

Steroid-free disease management

The present invention relates to the use of the compound 1-(2-(4-fluorophenyl)thiazol-5-yl)-1-(pyridin-4-yl)ethanol (“asnoo1”) in treatments without concomitant use of a steroid and/or in the form of a racemic mixture, e.g. In prostate cancer treatment.
Asana Biosciences, Llc

Salinosporamides and methods of use thereof

The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains cnb392 and cnb476 are effective inhibitors of hyperproliferative mammalian cells. The cnb392 and cnb476 strains lie within the family micromonosporaceae, and the generic epithet salinospora has been proposed for this obligate marine group.
The Regents Of The University Of California

Dna damage repair inhibitors for treatment of cancer

The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in hr dependent dna dsb repair. Methods and means relating to the treatment of cancers which are deficient in hr dependent dna dsb repair using inhibitors which target base excision repair components, such as parp, is provided herein..
Kudos Pharmaceuticals Limited

Curcuphenol compounds for increasing mhc-i expression

Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class i (mhc-i) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies..
Biommune Technologies Inc.

Method of selectively killing cancer cells using low-temperature plasma jet device and treating tumors using the same

A method of selectively killing cancer cells uses a low-temperature plasma jet device. When cancer cells are simultaneously treated with atr and parp-1 inhibitors, followed by synchronization of a circadian rhythm and treatment with low-temperature atmospheric-pressure plasma, cancer cell death may be maximized about ten-fold or more compared to when treated with existing low-temperature atmospheric-pressure plasma alone, and thus this method may be usefully used as a future tumor treatment method..
Dong-a University Research Foundation For Industry-academy Cooperation

Cancer cell detection method using living body-derived cells of biological origin

The purpose of the present invention is to provide a novel cancer cell detection method that uses living body-derived cells and that can be used even in cytodiagnosis. In particular, the purpose of the present invention is to provide a novel cancer cell detection method that makes it possible to perform imaging of cells in a living state and a dual detection method for cancer cells in which the aforementioned method is combined with a pre-existing dyeing method for cytodiagnosis.

Treatment of metastatic prostate cancer

The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (crpc). These new compositions include, but are not limited to, pharmaceutical compositions that include an ar-v7 inhibitor, such as niclosamide.

Method for screening compound specifically suppressing formation of caveolae of cancer cells, screening kit, vector and transformant to be used in kit, and selecting patient for whom molecularly targeted drug is indicated

Provided is a method for screening a compound that can specifically suppress the formation of caveolae of cancer cells and can inhibit the activity of various rtks using a single compound all at once. A method for screening a compound specifically suppressing the formation of caveolae of cancer cells wherein the screening method includes a step for bringing a test compound into contact with a system capable of detecting suppression of the binding of cavin-1 and cav1 and a step for selecting a compound having activity to suppress the binding of cavin-1 and cav1..

Methods for the diagnosis or prognosis of breast cancer

Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient ep-icd polypeptides and ep-icd polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear ep-icd polypeptides and optionally epex polypeptides are provided.

Cervical cancer-related hpv e7 protein monoclonal antibody and use thereof

The present invention provides an anti-hpv e7 protein monoclonal antibody and the use thereof. The antibody can detect the hpv16 e7 protein with high specificity and recognize the hpv18 e7 protein, thereby it can distinguish between the cancerous cervical epithelial cells and the cervical abnormal or non-cancerous cervical epithelial cells..

Serum-based mirna microarray and its use in diagnosis and treatment of barrett's esophagus (be) and esophageal adenocarcinoma (eac)

Robust and reliable molecular diagnostic screening tools for early detection of esophageal and gastrointestinal tract cancers and pre-cancerous lesions, such as barrett's esophagus, and esophageal adenocarcinoma are provided. Included in the invention is an array of mirna probes specific for identifying, diagnosing and prognosticating esophageal and gastrointestinal tract cancers and pre-cancerous lesions in subjects from blood or serum samples.

Antibodies against epidermal growth factor receptor (egfr) and uses thereof

Anti-egfr antibodies, therapeutic compositions comprising combinations of anti-egfr antibodies, as well as methods for using such antibodies and compositions to treat egfr-related disorders (e.g., cancers), are disclosed.. .

Specific expression of half-trna in cancers

The present invention relates to systems, devices and methods for diagnosing cancer. In various embodiments, the present invention provides a method for quantifying a 5′-htrna; a method for quantifying a 3′-htrna; a method for obtaining a dna library of 5′-htrnas and a dna library of 5′-htrnas obtained therefrom; and a method for obtaining a dna library of 3′-htrnas and a dna library of 3′-htrnas obtained therefrom.

Method of using near infrared fluorescent dyes for imaging and targeting cancers

The present invention describes methods of identifying, detecting, imaging, isolating and locating cancer cells in a subject. The method involves the use of near-infrared (nir) organic carbocyanine dyes, particularly, near infrared heptamethine cyanine dyes and the detection of the fluorescence of these nir dyes.

Direct and selective inhibition of mdm4 for treatment of cancer

The present application relates to the field of cancer, particularly that of cancers with high mdm4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of mdm4, e.g., by antisense rna, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies.

An lncrna and oncolytic adenovirus, and application thereof

Provided are an lncrna and oncolytic adenovirus, and application thereof. The oncolytic adenovirus is used as a carrier to express the lncrna, so as to express the lncrna in a cancer cell; competitively binding a target gene of oncomirs, and consuming the oncomirs, thus protecting a cancer suppressor gene from interference and suppression of the oncomirs, and achieving target intervention therapy of the cancer cell..

Methods of treating acute myeloid leukemia with antibodies to bone marrow stromal antigen 1

The invention provides antibodies which bind to the adp-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided.

Antibodies that specifically bind to tim3

Provided herein are antibodies specific for tim3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation..

Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

The present invention relates to therapeutic adcs comprising sn-38 attached to an anti-trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The adc is administered to a subject with a trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor.

Antigen binding proteins that bind pd-1

There is disclosed compositions and methods relating to or derived from anti-pd-1 antibodies. More specifically, there is disclosed fully human antibodies that bind pd-1, pd-1-binding fragments and derivatives of such antibodies, and pd-1-binding polypeptides comprising such fragments.

Treatment of cancers using anti-nkg2a agents

The present disclosure relates to hla-e as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably hla-e expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human nkg2a..

Reagents for detecting or diagnosing cancer cells having high invasive capacity

The present invention provides a reagent for detection or diagnosis of cancer, which comprises a monoclonal antibody against mct5 or a fragment thereof.. .

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec.

Mutagenic nucleoside analogs and uses thereof

The present disclosure provides nucleoside analogs of formula (i) or (ii). The nucleoside analogs are expected to show multiple tautomerism and may increase the mutation of an rna and/or dna (be mutagenic) of a virus or cancer cell.

Compounds, compositions, and methods for the treatment of cancers

The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (iv) complex having at least one polar moiety as a ligand..

Methods for treatment of resistant cancer

The present disclosure describes a method to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds of the invention can decrease the rate of proliferation of drug-resistant cancer cells, such as glioma, lung cancer, and uterine sarcoma..

Egfr inhibitor, preparation method and use thereof

Epidermal growth factor receptor (egfr) inhibitors are provided. In particular, 4-substituted-2-(n-(5-substituted allyl amide)phenyl)amino)pyrimidine derivatives of formula (i), a preparation method and use thereof as an egfr inhibitor are provided.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds.

Novel modulators of calcium release-activated calcium channel

Disclosed are novel calcium release-activated calcium (crac) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (nsclc) with crac inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer..

Methods and compositions related to retinoid receptor-selective pathway

Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenviroment.

Treatment of prostate cancer using enhanced energy application (eea) in high intensity focused ultrasound (hifu) procedures

A method for hifu treatment of localized prostate cancer in a patient includes identifying the cancer locations in a patient's prostate; visually segmenting the patient's prostate into areas for analysis and treatment, where the section including the area of most aggressive cancer is determined to be the primary area. The primary area is subjected to a first full hifu treatment for a period intended to ablate the cancerous tumor.

Electrochemical plasma activated aqueous chemotherapeutics

Methods for the generation of electrochemical plasma activated aqueous chemotherapeutics (epaac) solutions are described. These solutions have been found to selectively reduce the proliferation of human pancreatic cancer cells, with no toxic effects for healthy cells..

Method for egfr directed combination treatment of cancer

The present invention relates to a method of treating patients suffering from cancers driven by deregulated human epidermal growth factor receptor (her/human egfr), wherein an irreversible tyrosine kinase inhibitor (tki) is administered according to a continuous regimen based on an average daily dose in the range of 10 to 50 mg and the mab is co-administered according to a dosing regimen ranging from an average weekly iv dose of 50 to 500 mg/m2 repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least monthly to a patient in need of such treatment.. .

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

The present description relates to t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as igf2bp3-001 have the amino acid sequence of kiqeiltqv (seq id no:1).

Methods for treating cancers using ace inhibitors, arb, or celecoxib and olmesartan

Methods for treating cancers, such as breast cancer or skin cancer, using an ace or arb, or a combination of celecoxib and olmesartan.. .

Irisin-related cancer treatments

In one embodiment, the invention provides methods of treating or preventing cancer, in particular aspects breast and/or prostate cancer, by administering to a subject in need thereof a therapeutically-effective amount of irisin and, optionally, one or more adjuvant therapies (e.g. Synergistic co-administration of an additional anti-cancer agent or chemotherapy).

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A method of treating a patient who has gastric cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has gastric cancer.

Methods for treating cancer

The invention relates to nicotinamide riboside or a derivative thereof for use in the treatment and/or prevention of liver or pancreatic cancer in a subject. Additionally, the invention relates to an in vitro method for designing a customized therapy for a subject diagnosed with a liver cancer or pancreatic cancer or suffering early signs of chronic liver damage or pancreatic intraepithelial lesions based on determining the level of dna damage.

New indication of azelnidipine pharmaceutical composition for treating cancer

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of azelnidipine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, and skin cancer..

Diffuse acoustic confocal imager

A diffuse acoustic confocal imager device for use with a data analyzer for providing a three dimensional and state information on an object based on an at least one phase image, the device comprising a coherent acoustic source for producing an acoustic confocal beam ranging from about 0.5 megahertz to about 100 megahertz, an acoustic coherent beam focuser for focusing the acoustic coherent beam to a virtual source, an acoustic detector for detecting an at least one diffusely scattered beam from the virtual source and a vector network analyzer, which is for measuring a phase of the acoustic confocal beam and a phase of the at least one diffusely scattered beam to provide the at least one phase image, the vector network analyzer in electronic communication with each of the coherent acoustic source and the acoustic detector. A method of detecting and treating diseases such as prostate cancer and ovarian cancer is also provided..

Inhibitors of grb2-associated binding protein 1 (gab1) and methods of treating cancer using the same

Identification and evaluation of a set of first-in-class potent inhibitors targeting a new cancer target, grb2-associated binder˜1 (gab1), which integrates signals from different signaling pathways and is frequently over-expressed in cancer ceils. Intensive computational modeling is utilized to understand the structure of the gab1 pleckstrin homology (ph) domain and screened five million compounds.

Method and a kit to quantify and qualify exosomes for diagnosis of prostate cancer and prostate hyperplasia

A method and a kit are provided to quantify and qualify exosomes. Specifically the method and the kit quantify psa-carrying exosomes for a purpose to diagnose prostate cancer and to distinguish between patients having a tumor and those having a benign prostate condition with increased blood levels of psa.
Exosomics Siena S.p.a.

Immunohistochemistry quality management program using cultured cell lines for tissue microarray (tma) blocks

Provided are methods for producing a tissue microarray (tma) block from a mixture of cultured cell lines for use as an immunohistochemical control block in diagnosis and/or prognosis of one or more particular cancers. Provided are tissue microarray (tma) blocks for use as an immunohistochemical control block in diagnosing of one or more particular cancers.
Geisinger Health System

Methods and devices to study metabolism

Methods and devices to screen test compounds, e.g., study metabolism of test compounds, e.g., a pro-drug, by one cell, e.g., a hepatocyte, and the effect of metabolism of the test compound by the first cell on a second cell, e.g., a cancer cell, are described.. .
The General Hospital Corporation

Therapeutic, diagnostic, and prognostic methods for cancer

The invention provides methods and compositions to detect expression of one or more biornarkers, including fgfr3, tp53, and/or egfr, for treating, diagnosing, and providing a prognosis for cancer, e.g., bladder cancer. The invention also provides kits and articles of manufacture for use in the methods..
Genentech, Inc.

Predictive biomarker(s) of treatment with erb antibodies

The present disclosure includes methods for the prediction of outcome in breast cancer where egfr/erbb family members are over expressed and the benefit of treatment with an anti-erbb antibody. More specifically, the present invention relates the use of the mrna expression level of a c8a, or56a1, or prr20c biomarker compared to a reference expression level for providing information regarding the benefit of treatment with a her2 antibody, such as trastuzumab, in her2+ breast cancer..
Consortium For Clinical Diagnostics

Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met

The present invention provides methods for selecting a therapy for, or for providing a treatment to, a patient having a cancer. The methods of the present invention comprise detecting the protein biomarkers c-met, hgf, and epcam in cancer cells or cancerous tissues of a subject, and predicting the subject's responsiveness to treatment with a c-met-targeted or other hgf-inhibitory treatment, thereby enabling the selection and administration of an effective therapeutic..
Merrimack Phamaceuticals, Inc.

Salivary biomarkers for lung cancer detection

Presented herein are biomarkers related to lung cancer. The presently identified salivary biomarkers create the basis for a lung cancer detection bioassay with sensitivity and specificity.
The Regents Of The University Of California

High throughput sequencing

The invention relates to a high throughput method for determining telomere length of mammalian chromosomal dna; primers for use in said method; a kit comprising said primers; use of said method to diagnose or prognose or to determine the risk of developing a telomere shortening disease such as cancer, ageing, neurological disorders including alzheimer's disease, parkinson's disease and other dementias, brain infarction, heart disease, chronic hiv infection, chronic hepatitis, skin diseases, chronic inflammatory bowel disease including ulcerative colitis, anaemia, atherosclerosis, barrett's oesophagus and cancers including pre-cancerous conditions, infertility, telomere syndromes including dyskeratosis congenita, aplastic anaemia, idiopathic pulmonary fibrosis, familial myelodysplastic syndrome-acute myeloid leukaemia, hoyeraal-hreiderasson syndrome, revesz syndrome, coats plus syndrome, bone marrow failure, and cryptogenic liver cirrhosis. Additionally, the invention also has application in assessing an individual's suitability to be a transplantation donor, for example a bone marrow donor..

Pharmaceutical composition for treatment of cancer comprising rna oligonucleotide

The present disclosure provides a pharmaceutical composition for treating cancer comprising an rna oligonucleotide having a particular sequence and structure. Specifically, when a cell line is treated with an rna oligonucleotide having specific sequence and helical bend structure according to the present disclosure, the expression of isg56 is increased and apoptosis of cancer cells is induced.
Korea Advanced Institute Of Science And Technology

Anti-her3 antibodies and uses of same

An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human her-3 with a kd value of 10 nm or lower, wherein the polypeptide inhibits neuregulin (nrg) binding to the human hers and nrg-induced cancer cell migration and proliferation..
Yeda Research And Development Co., Ltd.

Prostate-specific membrane antigen binding proteins and related compositions and methods

The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (psma) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (bph). In one embodiment, the multi-specific polypeptide therapeutics bind both psma-expressing cells and the t-cell receptor complex on t cells to induce target-dependent t-cell cytotoxicity, activation and proliferation..
Aptevo Research And Development Llc

Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer

Bispecific antibodies against cd3epsilon and ror1 are useful for use in the treatmentof ovarian cancer.. .
Engmab Ag

Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis

The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-cd20 antibody with a cd22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of cd20 expressing cancers with an afucosylated humanized b-ly1 antibody and a cd22 antibody-drug conjugate.. .
Genentech, Inc.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.
Novartis Ag

Anti-cd100 antibodies and methods for using the same

Compositions and methods are provided for treating diseases associated with cd100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-cd100 monoclonal antibodies have been developed to neutralize cd100..
Vaccinex, Inc.

Cross reactive siglec antibodies

This invention relates to agents that bind multiple siglecs, including antibodies that neutralize the inhibitory activity of multiple siglec-7 and siglec-9 in lymphocytes. Such agents can be used for the treatment of cancers or infectious disease..
Innate Pharma

Monoclonal antibodies to progastrin and their uses

The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof.
Centre National De La Recherche Scientifique (cnrs)

Monoclonal antibodies to progastrin and their uses

The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof.
Centre National De La Recherche Scientifique (cnrs)

Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent

Methods are provided for improved treatment of subjects with cancer anorexia-cachexia syndrome, comprising treatment with a combination of at least one anti-cancer agent and at least one gdf 15 modulator. Methods are further provided for improved treatment of subjects with anti-cancer agents which induce cachexia, comprising further treating the subject with at least one gdf 15 modulator..
Aveo Pharmaceuticals, Inc.

Vascular endothelial growth factor fusion protein

The present invention relates to a fusion protein binding to a vascular endothelial growth factor (vegfr) and/or a placental growth factor (pigf). The fusion protein of the present invention comprises (a) a fc domain of igg1, wherein two heavy chains are linked by disulfide bond, and (b) four immunoglobulin domain2s of the vegfr1, wherein two immunoglobulin domain2s are sequentially fused to each heavy chain of the fc domain of (a).
Korea Prime Pharm Co., Ltd.

Cd44v6-derived peptides for treating metastasizing cancer

The present invention relates to compounds, pharmaceutical compositions and methods for treating different forms of pancreatic cancer.. .
Amcure Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary bladder cancer (ubc), and uterine cancer (uec) includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has hcc, crc, gb, gc, esophageal cancer, nsclc, pc, rcc, bph, pca, oc, melanoma, brca, cll, mcc, sclc, nhl, aml, gbc, ccc, ubc, and/or uec.
Immatics Biotechnologies Gmbh

Immunotherapy against melanoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the t cells bind to the peptide in a complex with an mhc class i molecule, and the composition is for treating the patient who has prostate cancer.
Immatics Biotechnologies Gmbh

Compositions and methods comprising rhenium for the treatment of cancers

Compositions and methods comprising rhenium are provided. In some embodiments, the rhenium compounds comprise a bidentate ligand.
Massachusetts Institute Of Technology

Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (irak4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (mll-r)

Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (mll-r), including mll-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (irak4)..
Northwestern University

Heteroaryl compounds comprising nitrogen and use thereof

The compounds according to the present invention exhibit a remarkable effect on inhibiting proliferation of cancer cells and metastasis and recurrence of cancer with a reduced dose compared to that of existing drugs. Accordingly, the compounds can be effectively used for treating various types of cancer, such as uterine cancer, breast cancer, gastric cancer, brain cancer, rectal cancer, colorectal cancer, lung cancer, skin cancer, blood cancer, pancreatic cancer, renal cancer, prostate cancer, bladder cancer, and liver cancer, and for inhibiting proliferation of cancer cells and metastasis of cancer..

Anticancer therapy

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions..
Stc.unm

Upar targeting peptide for use in peroperative optical imaging of invasive cancer

There is provided a novel conjugate that binds to the cell surface receptor upa (upar). The conjugate is based on a fluorescence-labeled peptide useful as a diagnostic probe to the surfaces of cells expressing upar.
Rigshospitalet

Antigen binding proteins that bind wisp1

There is disclosed compositions and methods relating to or derived from anti-wisp1 antibodies. More specifically, there is disclosed fully human antibodies that bind wisp1, wisp1-binding fragments and derivatives of such antibodies, and wisp1 binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases.
Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Cancer immunotherapy by immune activation or immune modulation via globo series antigens

The disclosure provides a method of immunotherapy for a cancer patient, comprises administering vaccines against globo series antigens (i.e., globo h, stage-specific embryonic antigen 3 “ssea3” and stage-specific embryonic antigen 4 “ssea4”). Specifically, the method comprises administering globo h-klh (obi-822) in patients with metastatic breast cancer.
Obi Pharma, Inc.

Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells

Disclosed are compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of nr2f6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use.
Regen Biopharma, Inc.

Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

A pharmaceutical composition contains an antibody or a fragment thereof specific for col6a3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition.
Immatics Biotechnologies Gmbh

New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of a cardiovascular drug or a pharmaceutical acceptable salt thereof. The cardiovascular drug is selected from the group consisting of peripheral vasodilator reaming enhancer, angiotensin converting agent inhibitor, hypotension and shock therapeutic agent, diuretic, antiarrhythmic agent, antiarralciton drug, antihypertensive agent, anticoagulant thrombolytic agent, cardiac tonic, and intravenous (hemorrhoids) therapeutic agent.
Launx Biomedical Co., Ltd.

New indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of an antibiotic drug or a pharmaceutical acceptable salt thereof. The antibiotic drug is selected from the group consisting of an aminoglycoside antibiotic drug, an anti-fungal antibiotic drug, a cephalosporin antibiotic drug, a β-propionamide antibiotic drug, a chloramphenicol antibiotic drug, an erythromycin antibiotic drug, a penicillin antibiotic drug, and a tetracycline antibiotic drug.
Launx Biomedical Co., Ltd.

Method for inhibiting survival, tumorigenesis and metastasis of cancer cells and/or cancer stem cells

A new method for preventing tumorigenicity or treating a cancer in a subject includes administering to the subject a collagen xvii (col xvii) inhibitor in an amount effective to inhibit and prevent survival, tumorigenesis and metastasis of cancer cells and/or cancer stem cells (cscs).. .

Methods of treating cervical cancer

This invention relates to the treatment of cervical tumor caused by human papillomavirus (hpv) infection. In particular, the invention provides methods for improving cervical tumor treatment and methods for treating cervical tumor caused by hpv infection using a polynucleotide encoding an e6/e7 fusion protein..
Genexine, Inc.

Oral iodine dosage form

Provided is an oral dosage form comprising a deliverable form of iodine for treating symptoms related to fibrocystic breast condition, for prophylactically maintaining breast health, for treating fibrocystic breasts or breast cancer in pre-menopausal women, for prophylactically maintaining prostate health, and for treating benign prostate hyperplasia along with related methods for making and administering such dosage form. More particularly, this disclosure relates to an oral dosage form that is effective to deliver supraphysiologic levels of molecular iodine.
Biopharmx, Inc.

Knottin-drug conjugates and methods of using the same

Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker.
The Board Of Trustees Of The Leland Stanford Junior University

Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug

A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-pom prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer.
The University Of Kansas

17a,21-diesters of cortexolone for use in the treatment of tumors

The present invention provides certain cortexolone derivatives of formula (i) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (i) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products..
Cosmo Technologies Ltd.

Quinoline derivative against non-small cell lung cancer

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1h-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival.
Advenchen Laboratories Nanjing Ltd.

New indication of paroxetine pharmaceutical composition for treating cancer

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of paroxetine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer.
Launx Biomedical Co., Ltd.

Therapeutic inhibitor for ebv-associated tumor with tailor responsive optical imaging

This invention provides a nucleus-permeable small-molecule inhibitor, l2p4 (where l2 is 4-(4-(diethylamino)styryl)-n-carboxymethylpyridinium chloride and p4 is an amino acid sequence comprising cahxyfmvfggrrrk and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of ebna1, a critical process for the growth of ebvs and the associated tumors. The present invention also provides method of treating and imaging ebv-associated cancers..
Hong Kong Baptist University

Endoxifen for local transdermal therapy to the breast

Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (dcis) using local transdermal therapy (ltt). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, n-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or enx) for treating breast cancer.
Northwestern University

New indication of cinacalcet hcl pharmaceutical composition for treating cancer

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of cinacalcet hcl or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer..
Launx Biomedical Co., Ltd.

Method of treating prostate cancer using a pkc inhibitor

The invention relates to compositions comprising a pkc inhibitor and their use in a method of treating or preventing the development of prostate cancer.. .

New indication of monobenzone pharmaceutical composition for treating cancer

A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising monobenzone or a pharmaceutical acceptable salt thereof. The cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, and skin cancer.
Launx Biomedical Co., Ltd.

Hepatocarcinoma metastasis therapy using hepatocarcinoma metastasis therapy apparatus

A liver cancer metastasis therapeutic device, consisting of a base plate, a prone support, an abdominal medicine massager, a chain wheel, a rotating wheel and a handheld massager, and being used in a treatment for restoring functions of a whole body; and the therapeutic device is focused on restoring the functions of the whole human body and complementarily performs chemoradiotherapy and surgery for killing cancer cells to treat causes of death, thus significantly reducing a death rate of patients due to metastasis of liver cancers and digestive organ cancers.. .

Gastroduodenal balloon tubes and methods for use in localized hypothermia

Materials and methods for producing localized hypothermia in a patient (e.g., for treatment of acute pancreatitis and pancreatic cancer).. .
Mayo Foundation For Medical Education And Research





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3591

file did exist - 13201

1 - 1 - 268